An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure

Circulation Research

Volumn 112, Issue 5, 2013, Pages 816-825

  Penn, Marc S ^a,b   Mendelsohn, Farrell O ^c   Schaer, Gary L ^d   Sherman, Warren ^e   Farr, Maryjane ^e   Pastore, Joseph ^f   Rouy, Didier ^f,g   Clemens, Ruth ^f   Aras, Rahul ^h   Losordo, Douglas W ⁱ  

^a SUMMA HEALTH SYSTEM   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c Center for Therapeutic Angiogenesis   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f Juventas Therapeutics Inc   (United States)

^g BioCardia Inc   (United States)

^h NORTHWESTERN MEMORIAL HOSPITAL   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

Author keywords

chemokine; chronic heart failure; clinical trial; gene transfer; stem cell

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; JVS 100; PLASMID DNA; PREDNISONE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

6 MINUTE WALK TEST; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DEPRESSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FOLLOW UP; GENE EXPRESSION; HEALTH CARE ORGANIZATION; HEART ARREST; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; ISCHEMIC CARDIOMYOPATHY; LOW DRUG DOSE; MALE; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT OUTCOME; TROPONIN I BLOOD LEVEL;

AGED; CHEMOKINE CXCL12; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; GENETIC THERAPY; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PLASMIDS; POSITRON-EMISSION TOMOGRAPHY; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84874763067     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.300440     Document Type: Article

References (54)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the american heart association. Circulation. 2009;121:e46-e215.
2. Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-146.
3. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin- converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
4. Penn MS, Dong F, Klein S, Mayorga ME. Stem cells for myocardial regeneration. Clin Pharmacol Ther. 2011;90:499-501.
5. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, Fichtner S, Korte T, Hornig B, Messinger D, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary autologous bonemarrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-148.
6. Schächinger V, Erbs S, Elsässer A, et al.; REPAIR-AMI Investigators. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27:2775-2783.
7. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011;108:792-796.
8. Perin EC, Willerson JT, Pepine CJ, et al.; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUSCCTRN trial. JAMA. 2012;307:1717-1726.
9. Traverse JH, Henry TD, Ellis SG, et al; Cardiovascular Cell Therapy ResearchNetwork. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306:2110-2119.
10. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362:697-703.
11. Penn MS, Zhang M, Deglurkar I, Topol EJ. Role of stem cell homing in myocardial regeneration. Int J Cardiol. 2004;95(suppl 1):S23-S25.
12. Deglurkar I, Mal N, Mills WR, Popovic ZB, McCarthy P, Blackstone EH, Laurita KR, Penn MS. Mechanical and electrical effects of cellbased gene therapy for ischemic cardiomyopathy are independent. Hum Gene Ther. 2006;17:1144-1151.
13. Unzek S, Zhang M, Mal N, Mills WR, Laurita KR, Penn MS. SDF-1 recruits cardiac stem cell-like cells that depolarize in vivo. Cell Transplant. 2007;16:879-886.
14. Dong F, Harvey J, Finan A, Weber K, Agarwal U, Penn MS. Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Circulation. 2012;126:314-324.
15. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002;30:973-981.
16. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3:687-694.
17. Penn MS. Importance of the SDF-1:CXCR4 axis in myocardial repair. Circ Res. 2009;104:1133-1135.
18. Saxena A, Fish JE, White MD, Yu S, Smyth JW, Shaw RM, DiMaio JM, Srivastava D. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation. 2008;117:2224-2231.
19. Sasaki T, Fukazawa R, Ogawa S, Kanno S, Nitta T, Ochi M, Shimizu K. Stromal cell-derived factor-1alpha improves infarcted heart function through angiogenesis in mice. Pediatr Int. 2007;49:966-971.
20. Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation. 2007;116:1683-1692.
21. Tang J, Wang J, Yang J, Kong X. Adenovirus-mediated stromal cellderived- factor-1alpha gene transfer induces cardiac preservation after infarction via angiogenesis of CD133+ stem cells and anti-apoptosis. Interact Cardiovasc Thorac Surg. 2008;7:767-770.
22. Hatzistergos KE, Quevedo H, Oskouei BN, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107:913-922.
23. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-1857.
24. Sundararaman S, Miller TJ, Pastore JM, Kiedrowski M, Aras R, Penn MS. Plasmid-based transient human stromal cell-derived factor-1 gene transfer improves cardiac function in chronic heart failure. Gene Ther. 2011;18:867-873.
25. Penn MS, Pastore J, Miller T, Aras R. SDF-1 in myocardial repair. Gene Ther. 2012;19:583-587.
26. de la Fuente LM, Stertzer SH, Argentieri J, Penaloza E, Koziner B, Rouy D, Altman PA. Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase I safety study (the Tabmmi study). EuroIntervention. 2011;7:805-812
27. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD investigators. JAMA. 1993;270:1702-1707.
28. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol. 1997;30:1589-1597.
29. de la Fuente LM, Stertzer SH, Argentieri J, Penaloza E, Miano J, Koziner B, Bilos C, Altman PA. Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow- up in an open-label, nonrandomized, single-center pilot study (the Tabmmi study). Am Heart J. 2007;154:79 e71-e77.
30. Badillo AT, Chung S, Zhang L, Zoltick P, Liechty KW. Lentiviral gene transfer of SDF-1alpha to wounds improves diabetic wound healing. J Surg Res. 2007;143:35-42.
31. Badillo AT, Zhang L, Liechty KW. Stromal progenitor cells promote leukocyte migration through production of stromal-derived growth factor 1alpha: a potential mechanism for stromal progenitor cell-mediated enhancement of cellular recruitment to wounds. J Pediatr Surg. 2008;43:1128-1133.
32. Deglurkar I, Mal N, Mills WR, Popovic ZB, McCarthy P, Blackstone EH, Laurita KR, Penn MS. Mechanical and electrical effects of cellbased gene therapy for ischemic cardiomyopathy are independent. Hum Gene Ther. 2006;17:1144-1151.
33. Rabbany SY, Pastore J, Yamamoto M, Miller T, Rafii S, Aras R, Penn M. Continuous delivery of stromal cell-derived factor-1 from alginate scaffolds accelerates wound healing. Cell Transplant. 2010;19:399-408.
34. Shyu WC, Lin SZ, Yen PS, Su CY, Chen DC, Wang HJ, Li H. Stromal cell-derived factor-1 alpha promotes neuroprotection, angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats. J Pharmacol Exp Ther. 2008;324:834-849.
35. Lotan D, Sheinberg N, Kopolovic J, Dekel B. Expression of SDF-1/ CXCR4 in injured human kidneys. Pediatr Nephrol. 2008;23:71-77.
36. Kollet O, Shivtiel S, Chen YQ, et al. HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. J Clin Invest. 2003;112:160-169.
37. Chiriac A, Terzic A, Park S, Ikeda Y, Faustino R, Nelson TJ. SDF-1- enhanced cardiogenesis requires CXCR4 induction in pluripotent stem cells. J Cardiovasc Transl Res. 2010;3:674-682.
38. Chiriac A, Nelson TJ, Faustino RS, Behfar A, Terzic A. Cardiogenic induction of pluripotent stem cells streamlined through a conserved SDF- 1/VEGF/BMP2 integrated network. PLoS ONE. 2010;5:e9943.
39. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res. 2011;108:792-796.
40. Strauer BE, Yousef M, Schannwell CM. The acute and long-Term effects of intracoronary stem cell transplantation in 191 patients with chronic heARt failure: the STAR-Heart study. Eur J Heart Fail. 2010;12:721-729.
41. Abraham WT, Fisher WG, Smith AL, et al; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-1853.
42. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
43. Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier AR, Böcker D, Block M, Kirkels JH, Kramer A, Huvelle E; Pacing Therapies in Congestive Heart Failure II Study Group; Guidant Heart Failure Research Group. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol. 2003;42:2109-2116.
44. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549.
45. Rostagno C, Olivo G, Comeglio M, Boddi V, Banchelli M, Galanti G, Gensini GF. Prognostic value of 6-minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation. Eur J Heart Fail. 2003;5:247-252.
46. Shah PB, Losordo DW. Non-viral vectors for gene therapy: clinical trials in cardiovascular disease. Adv Genet. 2005;54:339-361.
47. Fortuin FD, Vale P, Losordo DW, Symes J, DeLaria GA, Tyner JJ, Schaer GL, March R, Snell RJ, Henry TD, Van Camp J, Lopez JJ, Richenbacher W, Isner JM, Schatz RA. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol. 2003;92:436-439.
48. Kusano KF, Pola R, Murayama T, et al. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. Nat Med. 2005;11:1197-1204.
49. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg. 1999;68:830-836.
50. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE. Phase . placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002;105:2012-2018.
51. Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, SchmiederFA, Pilsudski R. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg. 2002;35:930-936.
52. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation. 1998;98:2800-2804.
53. Vale PR, Losordo DW, Symes JF, Isner JM. [Growth factors for therapeutic angiogenesis in cardiovascular diseases]. Rev Esp Cardiol. 2001;54:1210-1224.
54. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W, Bøtker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyöngyösi M, Sylvén C; Euroinject One Group. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol. 2005;45:982-988.